SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC

Condition(s) studied

Investigational drug(s) / intervention(s)

Spatially Fractionated Radiotherapy (SFRT): Several spherical volumes (with a diameter of 1 cm) are selected within the hypoxic area of the primary tumor. The distance between each spherical volume is 1.5 - 2 cm, and a high-dose radiotherapy of 12 Gy × 1F is delivered.

Tislelizumab, Carboplatin, Pemetrexed: For adenocarcinoma, pemetrexed (500 mg/m², day 1) + carboplatin (AUC 5, day 1) is used.

Tislelizumab, paclitaxel, Carboplatin: For NSCLC with pathological types other than adenocarcinoma, nab-paclitaxel (100 mg/m² on day 1 and day 8) + carboplatin (AUC 5, day 1) is used.

Study summary

The aim of this clinical trial is to understand whether spatial fractionated radiotherapy (SFRT) in combination with tislelizumab and platinum-based doublet chemotherapy given concurrently as induction treatment is effective in treating initially unresectable stage Ⅲ non-small cell lung cancer (NSCLC). It will also explore the safety of this treatment modality. The main questions it aims to answer are:

Will spatial fractionated radiotherapy (SFRT) in combination with tislelizumab and platinum-based doublet chemotherapy given concurrently as induction treatment increase the surgical resection rate of patients with initially unresectable stage Ⅲ non-small cell lung cancer? What adverse reactions will patients experience when receiving spatial fractionated radiotherapy (SFRT) in combination with tislelizumab and platinum-based doublet chemotherapy given concurrently as induction treatment?

Eligibility

Primary outcome measure(s)

• Surgical resection rate — At the end of the surgery
  The percentage of patients who underwent surgical resection after induction treatment

Trial sites (1)

More Second Affiliated Hospital of Nanchang University trials in China

Other trials for the same condition